Stéphane Thiroloix
Founder at Algotherapeutix SAS
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edmund Harrigan | M | 71 |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 3 years |
| Scott A. Byrd | M | 54 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
| Karen Witts | F | 61 |
Ipsen Pharma SA
 Ipsen Pharma SA Pharmaceuticals: MajorHealth Technology Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain. | - |
| Alain Haut | M | - |
Ipsen Pharma SA
Ipsen Pharma SA Pharmaceuticals: MajorHealth Technology Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain. | - |
| Thibaut Roulon | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
| Hugues le Bret | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 5 years |
| Pierre Boulud | M | 52 |
Ipsen Pharma SA
Ipsen Pharma SA Pharmaceuticals: MajorHealth Technology Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain. | - |
| Claire Poulard | F | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Victoire Jacquin de Margerie | M | 61 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Olivier Jean Bohuon | M | 65 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 years |
| Jean-Yves Parisot | M | 60 |
École des Hautes Études Commerciales de Paris
| 6 years |
| François Jean Henri Pinault | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Corinne M. Saunders | F | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Olivier Aubert | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Sofia Merlo | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Alexandra Soto | F | 55 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean Thouvenin | F | - |
École des Hautes Études Commerciales de Paris
| 2 years |
| Olivier Ceccarelli | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Nicolas S. Weill | M | - |
École des Hautes Études Commerciales de Paris
| 1 years |
| Valérie Hermann | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Melchior de Vogüe | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Pierre Casamatta | M | 59 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Frédéric Rozé | M | 63 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Marc-Emmanuel Vives | M | 62 |
École des Hautes Études Commerciales de Paris
| 1 years |
| Yves Leclère | M | 74 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Eric Berthelot | M | 63 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Jacques van Zuylen | M | - |
École des Hautes Études Commerciales de Paris
| 6 years |
| Marie-Aude de Bonnières | F | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Pascal Claude Auge | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Pierre du Baret | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Kareen Ceintre | M | 60 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Nicolas Bontemps | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Pierre Gaucher | M | - |
École des Hautes Études Commerciales de Paris
| 2 years |
| Nicolas Pierre Yves Sartini | M | 63 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Dominique Potier Bassoulet | F | 63 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Vincent Fleury | M | - |
École des Hautes Études Commerciales de Paris
| 3 years |
| Corinne Fernandez Handelsman | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Géry Robert-Ambroix | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Damien Faucher | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Jérôme Guiraud | M | 63 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Gérard Kuperfarb | M | - |
École des Hautes Études Commerciales de Paris
| 1 years |
| Olivier Wigniolle | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Alain Vigeant | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-Luc Allavena | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Marie-Christine Ducholet | F | 61 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Eduardo Mazzilli de Vassimon | M | 65 |
École des Hautes Études Commerciales de Paris
| 1 years |
| Nathalie Rouvet-Lazare | F | 76 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Béatrice Marie Derouvroy-Bernard | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-Marc Pambet | M | 65 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Catherine Gérardin-Vautrin | F | 64 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Laurent Boissel | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Marc Blais | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Pascal Cagni | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Pierre de Villeméjane | M | 56 |
École des Hautes Études Commerciales de Paris
| 3 years |
| Marc Fiorentino | M | 64 |
École des Hautes Études Commerciales de Paris
| 1 years |
| Lucile Ribot | F | 57 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Frédéric Daniel Sanchez | M | 64 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-Michel Dupiot | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Yann Leca | M | 57 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-Jacques Guiony | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Guillaume Lévy-Lambert | M | - |
École des Hautes Études Commerciales de Paris
| 1 years |
| Laurent Mignon | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-François Palus | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Olivier Rudigoz | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Patrick Tanguy | M | 64 |
École des Hautes Études Commerciales de Paris
| 4 years |
| David Baverez | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Philippe Schaison | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Corinne Pollier-Bousquet | F | 59 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Jean-François Labbé | M | 73 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
| Jean-Paul Castaigne | M | 79 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Eric Etchart | M | 67 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Yves Marque | M | 57 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Didier Lévêque | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Arnaud Raimon | M | 60 |
École des Hautes Études Commerciales de Paris
| 3 years |
| Frédéric Lemoine | M | 59 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Henri Viard | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Christophe Cuvillier | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Odile Roujol | M | - |
École des Hautes Études Commerciales de Paris
| 3 years |
| Jacques Richier | M | 69 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Xavier Rene Louise Girre | M | 55 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Frédéric Lavenir | M | 64 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Philippe Dumont | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Lise Nobre | F | 58 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Eric Marcel Xavier Pichet | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Éric Blanc-Garin | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Patrick Arrosteguy | M | 71 |
École des Hautes Études Commerciales de Paris
| 2 years |
| Philippe Rosio | M | 64 |
École des Hautes Études Commerciales de Paris
| 4 years |
| Claude Charron | M | - |
École des Hautes Études Commerciales de Paris
| 4 years |
| Virginie Helias | F | 59 |
École des Hautes Études Commerciales de Paris
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 86 | 96.63% |
| Spain | 3 | 3.37% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stéphane Thiroloix
- Personal Network
